





FIG. 1






FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4A

VIDA MEDIA PROLONGADA DEMOSTRADA EN NHPs




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 5A

Liberación de IFN_γ dependiente de TL1A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 6C

Concentración de Anticuerpo (mg/mL)

Viscosidad




FIG. 7A




FIG. 7B

Valores absolutos

	Donante			
	1	2	3	4
IC50 ng/ml				promedio
RVT-3101	70,2	32,8	29,1	34,1
MK-7240	91,4	264,9	408,8	135,8
Anticuerpo 19	23,3	8,1	21,5	9,5
Anticuerpo 47	22	4,7	28,8	38
Anticuerpo 49	10,429	94,742	17,206	14,773
Anticuerpo 63	9,7	10,1	6,8	5,8
Anticuerpo 86	37,6	11,4	25,5	28,6
Anticuerpo 92	76,137	2,732	18,905	32,293

Donante

	Donante			
	1	2	3	4
Normalizado a PF				promedio
MK-7240	1,30	8,08	14,05	3,98
Anticuerpo 19	0,33	0,25	0,74	0,28
Anticuerpo 47	0,31	0,14	0,99	1,11
Anticuerpo 49	0,15	2,89	0,59	0,43
Anticuerpo 63	0,14	0,31	0,23	0,17
Anticuerpo 86	0,54	0,35	0,88	0,84
				0,65

FIG. 7C




FIG. 7D




FIG. 7E

Valores absolutos

	Donante			
	1	2	3	4
IC50 ng/ml				promedio
RVT-3101	70,2	32,8	29,1	34,1
MK-7240	91,4	264,9	408,8	135,8
Anticuerpo 8	32,344	7,950	27,735	21,729
Anticuerpo 10	21,5	5,6	20	10,8

	Donante			
	1	2	3	4
Normalizado a PF				promedio
MK-7240	1,30	8,08	14,05	3,98
Anticuerpo 8	0,46	0,24	0,95	0,64
Anticuerpo 10	0,31	0,26	0,69	0,32

FIG. 7F





FIG. 8A



TL1A monómero 1
 TL1A monómero 2
 TL1A monómero 3
 Anticuerpo 10
 DR3 (modelo de homología)

FIG. 8B